Why Immunovant (IMVT) Is Up 15.1% And What's Next
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Immunovant (IMVT) saw a 15.1% increase following its Q2 report, which included a net loss of US$97.25 million but positive topline data for IMVT-1402 in rheumatoid arthritis and early commercial revenue for LISRAYA. The company also announced a US Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context